pharma news today obesity drugs glp-1 october 2025 Eli Lilly set to leapfrog Novo Nordisk in weight-loss drug race Obesity GLP-1 Market

The findings from two clinical trials suggest that a lower dose of GLP-1 drugs, or switching to an oral pill like Foundayo, can help to maintain weight loss.

The European Cardiovascular Health Plan Roadmap from the European Alliance was published earlier in 2025 and calls for comprehensive approaches to incorporate the recognition of obesity as a trigger for cardiovascular disease

Medically supervised GLP-1 weight loss in Oswego, IL

Records were reviewed for patient characteristics and medication type and doses

/PRNewswire/ -- Ro, the leading direct-to-patient healthcare company, today announced eligible patients can now access Foundayo (orforglipron) Eli Lilly...